Stratec Se (SBS.DE) Azione Prezzo
Stratec Se Prezzo
Il fatturato è cresciuto a un tasso composto del 7,6% annuo negli ultimi 18 anni, raggiungendo 250,86 Mio. EUR. L'utile per azione è cresciuto del 5,8% all'anno negli ultimi 16 anni. Il margine netto di Stratec Se si attesta al -0,1%, in calo rispetto al 13,9% di alcuni anni fa. Stratec Se offre attualmente un rendimento da dividendo di circa il 2,55%. Il dividendo è cresciuto del 9,9% all'anno negli ultimi 19 anni. Gli analisti fissano un target di prezzo mediano di 31,11 EUR, ovvero il 32,4% sopra il prezzo attuale. Su 11 analisti, 8 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Stratec Se Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Stratec Se Azione e analisi azionaria
Domande frequenti sull'azione Stratec Se
The business model of Stratec SE revolves around providing innovative solutions and services to the diagnostics industry. As a leading global technology partner, Stratec SE specializes in developing and producing automated analyzer systems that enable fast, reliable, and cost-effective diagnostics. By focusing on instrument and assay integration, Stratec SE helps its customers streamline their processes and improve laboratory efficiency. The company's comprehensive portfolio covers a wide range of applications, including clinical diagnostics, blood banking, and pharmaceutical quality control. With its expertise and cutting-edge technologies, Stratec SE aims to drive advancements in diagnostics and contribute to improving patient care worldwide.
Stratec SE is primarily active in the life sciences and medical technology industries.
The main competitors of Stratec SE in the market include companies like Thermo Fisher Scientific, Becton, Dickinson and Company, PerkinElmer Inc., and Bio-Rad Laboratories.
Stratec SE, a leading global supplier of laboratory automation and diagnostic solutions, has a rich history and background. Established in 1979 in Birkenfeld, Germany, the company has grown from a small start-up to a renowned player in the life science industry. Stratec SE specializes in developing innovative technologies and devices that enable faster and more efficient diagnostics and research processes. With a strong focus on customer satisfaction and strategic partnerships, Stratec SE has expanded its presence worldwide. Today, the company serves a diverse range of customers, including pharmaceutical firms, medical device manufacturers, and research institutions. Stratec SE's dedication to technological advancement and commitment to quality make it a trusted name in the industry.
Stratec SE, a renowned stock company, has accomplished several notable milestones throughout its journey. One prominent achievement is the successful development of innovative laboratory and diagnostic solutions for the global healthcare industry. Stratec SE has also gained recognition for its strategic partnerships and collaborations, fostering growth and expanding its market presence. Moreover, the company has consistently delivered strong financial performance, achieving sustainable revenue growth and enhancing shareholder value. Stratec SE's commitment to continuous innovation, dedication to quality, and focus on customer satisfaction has positioned it as a key player in the industry, ensuring its ongoing success and reputation as a trusted stock investment.
Stratec SE is primarily present in various countries and regions. As a global company, its presence extends across Europe, North America, and Asia. Stratec SE operates in countries such as Germany, Switzerland, the United States, China, and Japan, among others. With its strong international footprint, Stratec SE has established itself as a leading provider of innovative solutions in the fields of in-vitro diagnostics and life sciences.
Stratec SE represents a strong set of values and corporate philosophy. With a focus on innovation and quality, the company aims to provide cutting-edge solutions in the field of automation and instrumentation for medical diagnostics. Stratec SE puts a strong emphasis on customer satisfaction and long-term partnerships, striving for continuous improvement and excellence. By fostering a culture of collaboration, integrity, and professionalism, the company aims to drive sustainable growth and deliver value to its shareholders. Stratec SE's commitment to delivering high-performance products and services, coupled with its dedication to corporate responsibility, sets it apart in the industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 34,95 EUR per l’azione Stratec Se (mediana: 31,11 EUR), pari a +48,7 % rispetto all’ultimo prezzo. Il consenso si basa su 11 giudizi di analisti.
11 analisti valutano attualmente l’azione Stratec Se: 8 raccomandano l’acquisto, 3 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Stratec Se ricavi pari a 266,95 Mio. EUR e un utile per azione di 1,42 EUR.
L’azione Stratec Se (SBS.DE) è quotata su 8 borse, tra cui: London (0RAR.L), SIX (Zürich) (SBS.SW), XETRA (SBS.DE), Frankfurt (SBS.F), München (SBS.MU), Düsseldorf (SBS.DU), Hamburg (SBS.HM).
Stratec SE is a leading provider of automation solutions for the diagnostic and analytic industry. The company offers a wide portfolio of products and services that are part of its core business. Stratec operates in two business segments: instrumentation and diagnostics. (Instrumentation) Stratec offers a wide range of automation solutions, including the development, production, and distribution of equipment and systems for automated sample processing in clinical laboratories, as well as industrial automation for the production of medical devices and system solutions in the fields of life science and diagnostics. The company is a market leader in immunology and hematology and is also present in other segments such as microbiology and molecular biology. (Diagnostics) The diagnostic business segment provides specialized immunological and molecular tests for a variety of medical applications in the in vitro diagnostic (IVD) market. The company focuses on immuno-oncology, gastroenterology, infectious diseases, and cardiovascular diseases. Stratec offers comprehensive development, production, quality control, life cycle, and market release management services. The company emphasizes close collaboration with its customers to develop innovative solutions of the highest quality that meet the highest requirements for precision, reliability, and scalability. Stratec has demonstrated its resilience, successfully navigating through the COVID-19 pandemic in 2020. The company has proven to be crisis-resistant and has guided its employees through the crisis. With a strong global presence and industry-specific expertise, Stratec is able to continuously meet customer requirements. The company has established its business in the United Kingdom and the United States and plans to expand into other countries, primarily in Asia. Wherever Stratec operates, it emphasizes open and collaborative partnerships with customers and other stakeholders. Overall, Stratec SE is a company that impresses with its comprehensive automation solutions for the diagnostic and analytic industry. The instrumentation business segment covers multiple areas of medicine, while the diagnostics business segment specializes in the development and production of diagnostic solutions. Together, both segments enable optimal collaboration with customers and comprehensive expertise in the industry. The company is capable of addressing both customer needs and industry requirements as a whole.
Il attesa fatturato di Stratec Se ammonta a 266,95 Mio. EUR. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Stratec Se ammonta a 17,21 Mio. EUR. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Stratec Se è attualmente 16,60. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Stratec Se.
Il rapporto prezzo/fatturato (P/S) di Stratec Se è attualmente 1,07. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Stratec Se.
Il Quality Score AlleAktien per Stratec Se è 1/10.
L'ISIN di Stratec Se è DE000STRA555. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Stratec Se è STRA55. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Stratec Se è SBS.DE. Con questo simbolo di borsa vengono negoziate le azioni Stratec Se in borsa.
Azione Stratec Se
Gruppo di pari di Stratec Se
Stratec Se Ticker
Stratec Se FIGI
Altre metriche e analisi di Stratec Se in Deep Dive.
La nostra analisi azionaria dell'azione Stratec Se include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Stratec Se. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: